Robert Miller, Chief Medical Science Officer at CancerLinQ shared on LinkedIn:

“When I was in practice, I had a number of patients with curatively-treated early stage breast cancer ask if they should take a daily aspirin to reduce the risk of recurrence, based on a number of observational studies and at least 1 meta-analysis suggesting improved disease-free survival.

Given the lack of definitive evidence, I usually said I did not advise it. An additional consideration was the small risk of a serious Gastrointestinal or CNS bleeding complication. This interventional study that came out yesterday in JAMA seems to confirm a lack of benefit with ASA, as invasive disease–free survival events, including death, invasive progression (both distant and locoregional), and new primary events were numerically HIGHER in the aspirin group – yikes (although not statistically significant).

Disappointing, but this is why we need randomized, prospective trials for many questions…”

Further Reading.
Source: Robert Miller/LinkedIn